These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6110217)

  • 41. The brief psychiatric rating scale: effect of scaling system on clinical response assessment.
    Thompson PA; Buckley PF; Meltzer HY
    J Clin Psychopharmacol; 1994 Oct; 14(5):344-6. PubMed ID: 7806691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S; Iwamoto N; Arai H
    Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of neuroleptics and tricyclic antidepressants upon d-amphetamine discrimination.
    Schechter MD
    Pharmacol Biochem Behav; 1980 Jan; 12(1):1-5. PubMed ID: 6102768
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
    Janssen PA; Awouters FH
    Arzneimittelforschung; 1994 Mar; 44(3):269-77. PubMed ID: 7514873
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amphetamine psychosis: behavioral and biochemical aspects.
    Angrist B; Sathananthan G; Wilk S; Gershon S
    J Psychiatr Res; 1974; 11():13-23. PubMed ID: 4461784
    [No Abstract]   [Full Text] [Related]  

  • 47. Dextro-amphetamine diminishes negative symptoms in schizophrenia.
    van Kammen DP; Boronow JJ
    Int Clin Psychopharmacol; 1988 Apr; 3(2):111-21. PubMed ID: 3294284
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo.
    Ichikawa J; Meltzer HY
    Brain Res; 1992 Mar; 574(1-2):98-104. PubMed ID: 1379112
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of neuroleptics with central dopamine and noradrenaline receptor blocking properties in the L-DOPA and (+)-amphetamine-induced waking EEG in the rat.
    Monti JM
    Br J Pharmacol; 1979 Sep; 67(1):87-91. PubMed ID: 40644
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Alexithymia in negative symptom and non-negative symptom schizophrenia].
    Nkam I; Langlois-Thery S; Dollfus S; Petit M
    Encephale; 1997; 23(5):358-63. PubMed ID: 9453928
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Pharmacologic approach to negative symptoms in schizophrenia].
    Jalenques I
    Encephale; 1995 Jun; 21 Spec No 3():35-40. PubMed ID: 7628340
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics.
    Huttunen MO; Tuhkanen H; Haavisto E; Nyholm R; Pitkänen M; Raitasuo V; Romanov M
    Psychiatr Serv; 1996 Jan; 47(1):83-5. PubMed ID: 8925352
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.
    Kane JM; Marder SR; Schooler NR; Wirshing WC; Umbricht D; Baker RW; Wirshing DA; Safferman A; Ganguli R; McMeniman M; Borenstein M
    Arch Gen Psychiatry; 2001 Oct; 58(10):965-72. PubMed ID: 11576036
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stability of positive and negative symptom constructs during neuroleptic treatment in schizophrenia.
    Goldman RS; Tandon R; Liberzon I; Goodson J; Greden JF
    Psychopathology; 1991; 24(4):247-52. PubMed ID: 1754657
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Supersensitivity of d-amphetamine-induced hyperthermia in rats following continuous treatment with neuroleptics.
    Norman AB; Wylie GL; Prince AK
    Eur J Pharmacol; 1987 Aug; 140(3):349-51. PubMed ID: 2888671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Profile of the action of neuroleptics in deficit schizophrenia].
    Vanelle JM
    Encephale; 1996 Jun; 22 Spec No 2():33-9. PubMed ID: 8767040
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evidence for onset of antipsychotic effects within the first 24 hours of treatment.
    Kapur S; Arenovich T; Agid O; Zipursky R; Lindborg S; Jones B
    Am J Psychiatry; 2005 May; 162(5):939-46. PubMed ID: 15863796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.